Find Academic Supervisors

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +3 more

Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.

• DNA Damage and Repair
• Aging Mechanisms
• Cancer Biology
• +6 more

Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.

• Membrane Protein Structure and Function
• G Protein-Coupled Receptors (GPCRs)
• Lipid-Protein Interactions
• +3 more

Andrew Regan is a Senior Lecturer in the School of Chemistry at the University of Manchester, specializing in organic synthesis and drug discovery. He holds a B.A. (1981), M.A. (1985), and Ph.D. (1985) from the University of Cambridge. His career includes postdoctoral research at Columbia University and a lectureship at the University of Kent before joining Manchester in 1991. Research interests focus on synthesizing biologically active compounds, such as phosphinic acids for anticancer agents, and developing novel synthetic methods. His work contributes to drug discovery, green chemistry, and efficient chemical processes. He currently supervises two PhD students researching phosphinic acid analogues and simplified erythromycin analogues. Key achievements include the synthesis of epibatidine and advancements in macrolide antibiotic design. His research aligns with sustainable development goals through eco-friendly synthesis methods.

• Drug Discovery
• Organic Synthesis
• Biologically Active Compounds
• +5 more

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +4 more

Prof. Dr. Deniz Tasdemir is a Full Professor (W3) of Marine Natural Products Chemistry at GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel and serves as Director of the GEOMAR-Biotech center and Head of the Marine Natural Product Chemistry Research Unit. Her career spans institutions including the National University of Ireland Galway and UCL School of Pharmacy. PhD in Pharmacy, ETH Zurich (1997) Post-doctoral work, University of Utah (2001) Dr. Helmut Legerlotz Fellowship, University of Zurich (2002-2025) Her research focuses on marine chemical ecology , metabolomics , and bioprospecting for bioactive compounds from sponges, algae, and marine microbiomes. Recent work explores seagrass pathogen reduction, microbiome interactions, and aquafeed applications. Scientific awards include: Waters Award for Natural Products Innovation (2016) Egon Stahl Silver Medal (2005) Pierre Fabre Prize (2004) ETH Zurich Medal (1997) She leads collaborative projects on ocean sustainability and marine drug discovery, with editorial roles in Marine Drugs , Planta Medica , and Phytochemistry Letters .

• Marine Natural Products Chemistry
• Marine Ecology
• Biodiscovery
• +2 more

JIANG Xingyu is Chair Professor and Head of the Department of Biomedical Engineering at the Southern University of Science and Technology (SUSTech) . Since 2018 he has led a multidisciplinary team developing advanced micro- and nano-scale tools for analytical chemistry, microfluidics and nanomedicine. Education Postdoctoral Research, Harvard University (2004–2005) Ph.D. in Chemistry, Harvard University (2004) B.S. in Chemistry, University of Chicago (1999) Research Interests Professor Jiang’s research integrates analytical chemistry , microfluidics , biomedical engineering and nanomedicine . His laboratory designs microfluidic chips for point-of-care diagnostics, engineers gold nanoclusters and nanoparticles for antimicrobial and anticancer therapy, and develops soft flexible bio-electronics for neural interfaces and wearable health monitoring. Across 400+ publications, recent work demonstrates a clear trend toward translational nanomedicine : point-of-care viral variant detection, nanoantibiotic strategies against multidrug-resistant bacteria, CRISPR delivery systems for cancer therapy, and conformal electronic tattoos for human-machine interfaces. Scientific Awards & Honours Fellow, American Institute for Medical and Biological Engineering (2020) Fellow, Royal Society of Chemistry (2016) Tencent Science Exploration Award (2019) Chief Scientist, National Key R&D Program (2019–) National Science Fund for Distinguished Young Scholars (2010) Young Investigator Award, Human Frontier Science Program (2007) Research Funding & Teams He currently directs the Nanoscience Laboratory at SUSTech, hosts National Key R&D Program projects as Chief Scientist, and serves on editorial boards of Advanced Healthcare Materials , Lab on a Chip , Nanoscale Horizons , Nanoscale and Nanoscale Advances . The group is actively recruiting post-docs, research professors and technicians across chemistry, materials, biology and medical engineering disciplines.

• Analytical Chemistry
• Microfluidics
• Biomedical Engineering
• +2 more

Ashis K. Patra is a full-time Professor in the Department of Chemistry at the Indian Institute of Technology Kanpur (IIT Kanpur). After obtaining his Ph.D. from the Indian Institute of Science (IISc) Bangalore in 2008, he carried out post-doctoral research at Harvard University and the University of Georgia before joining IIT Kanpur in 2012. Education & Academic Training Ph.D. (2008), Indian Institute of Science (IISc), Bangalore M.Sc. (2002), The University of Burdwan Research Interests Professor Patra leads an interdisciplinary program that sits at the interface of inorganic chemistry, chemical biology, and medicinal chemistry. His work is organized into three principal thrusts: Therapeutic Applications of Metal Complexes: Design and mechanistic evaluation of cytotoxic transition-metal complexes that target nucleic acids and proteins, aiming to overcome multidrug resistance in cancer. Nitric Oxide Delivery from Transition Metal Nitrosyls: Development of photo- and redox-triggered metal nitrosyl complexes for controlled NO release to biological targets such as hemoglobin, myoglobin, and glutathione. Luminescent Lanthanide Complexes: Synthesis and photophysical characterization of Eu(III) and Tb(III) complexes that serve as luminescent probes and theranostic agents. Research Output & Impact His group has published extensively in leading journals including Dalton Transactions , Inorganic Chemistry , Chemical Science , and Journal of Inorganic Biochemistry . The collective work demonstrates a clear trajectory from fundamental coordination chemistry to translational applications in drug delivery and bioimaging, with recurring themes of redox control, light activation, and biological targeting. Scientific Awards & Fellowships CSIR Junior & Senior Research Fellowships (2001, 2003) West Bengal SLET Qualification (2001) International Travel Grants from CSIR & INSA (2006) DST Fast-Track Fellowship for Young Scientists (2013) Erasmus Mundus NAMASTE Scholarship for Academic Staff (2014) JSPS Invitation Fellowship (2016) Teaching & Mentoring Professor Patra teaches core and advanced courses in inorganic chemistry, including Inorganic Chemistry Laboratory, Bioinorganic Chemistry, and Frontiers in Inorganic Chemistry. He actively mentors Ph.D. and master’s students (full list available on his lab website ) and has established the Laboratory of Inorganic Chemical Biology in the Old Core Lab complex at IIT Kanpur.

• Inorganic Chemistry
• Bioinorganic Chemistry
• Therapeutic Applications of Metal Complexes
• +3 more

Brent Page is an Associate Professor (tenured) in the Faculty of Pharmaceutical Sciences at the University of British Columbia (UBC) and maintains a research group at the Karolinska Institute , Department of Oncology and Pathology. His dual affiliation underpins a trans-Atlantic program that integrates cutting-edge chemical biology with medicinal chemistry for anti-cancer drug discovery. Education & Training PhD in Chemistry – University of Toronto (2013) HBSc in Chemistry (Honours) – University of British Columbia (2008) CIHR Postdoctoral Fellow – Karolinska Institute, Sweden (2008–2016) Assistant Professor (non-independent) – Karolinska Institute, Department of Oncology-Pathology (2017–2021) Research Focus Dr. Page’s laboratory operates at the interface of medicinal chemistry and chemical biology , aiming to identify and optimize small-molecule inhibitors for proteins previously considered “undruggable.” Core targets include STAT3, CLIC3, NUDT5/15 and SRPK3 . The group employs cellular thermal shift assays , isothermal ligand-induced resolubilization (ILIRA) , and CeTEAM technologies to quantify target engagement and refine structure–activity relationships in physiologically relevant models of breast cancer, triple-negative breast cancer, leukemia and atopic diseases . Funding & Collaborations His program is supported by Canadian Institutes of Health Research (CIHR) and other national and international agencies. Dr. Page actively participates in UBC’s Accelerated Translational Opioid Research Cluster and welcomes interdisciplinary collaborations and undergraduate research involvement. Equity, Diversity & Inclusion Committed to fostering an inclusive environment, Dr. Page mandates EDI training for all lab members and actively encourages participation from equity-deserving groups.

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery and Development
• +13 more

Yu He is an Assistant Professor of Applied Physics and Physics at Yale University, affiliated with the Department of Physics. His research focuses on condensed matter physics and experimental techniques such as angle-resolved photoemission spectroscopy (ARPES) and x-ray scattering to study correlated electronic systems and quantum materials. Prior to Yale, he completed a Miller Research Fellowship at UC Berkeley (2019) after earning his Ph.D. in Applied Physics from Stanford University. Key research areas include metal-to-insulator transitions, superconductivity, 2D magnetism, and solid-state quantum simulation. He has contributed to advancements in material characterization techniques, including high-resolution ARPES using tabletop lasers. His work integrates crystal synthesis, electric transport measurements, and surface decoration to explore material properties. Education: B.S. in Physics from University of Science and Technology of China (USTC); M.S. in Electrical Engineering and Ph.D. in Applied Physics from Stanford University. Research Interests: Experimental condensed matter physics, quantum materials, superconductivity, and light-matter interaction studies. His current projects aim to dissect microscopic degrees of freedom (electronic, lattice, spin) in novel materials using cutting-edge spectroscopic methods. The lab employs complementary techniques like electric transport measurements and crystal growth to characterize material properties comprehensively. Awards: Miller Research Fellow, UC Berkeley (2019) Advising & Grants: No student advisees listed. Research supported by Yale University and prior fellowships. Labs & Teams: Leads a research group at Yale focused on experimental condensed matter physics, collaborating on projects involving advanced material characterization and quantum material discovery.

• Condensed Matter Physics
• Quantum Materials
• Superconductivity
• +3 more

Herman Sintim is the Grace-Rupley Professor of Chemical Biology in the Department of Chemistry and Biochemistry at the University of Notre Dame, where he also serves as the Associate Director of the Harper Cancer Research Institute. He has previously held faculty positions at Purdue University and the University of Maryland at College Park, progressing from Assistant to Full Professor. His research is highly interdisciplinary, bridging organic chemistry, chemical biology, and drug discovery. Research Interests: Dr. Sintim's research focuses on understanding and modulating cyclic dinucleotide signaling pathways in both bacteria and mammalian immune systems. His lab explores the roles of molecules like c-di-GMP, c-di-AMP, and cGAMP in biofilm formation, virulence, and immune activation, particularly via the STING pathway. A major thrust is the development of small molecule probes and therapeutics targeting these pathways for use in cancer immunotherapy and as novel antibiotics. Additionally, his group pioneers the synthesis of new kinase inhibitors using multi-component reactions to combat drug resistance in cancer, targeting kinases such as FLT3, CDKs, and RET. The recent publications of the Sintim group reflect a strong trend in designing novel chemotypes for both STING modulation (agonists and antagonists) and kinase inhibition, with an emphasis on oral bioavailability and efficacy in animal models. These works span chemical synthesis, biochemical evaluation, and translational applications in oncology and immunology. Scientific Awards: Lafayette Lions Club Cancer Research Award (2022) Sigma Xi Distinguished Lecturer (2015) Camille Dreyfus Teacher-Scholar Award (2011) Allen Angerio Award for Excellence in Faculty Mentorship (2010) Kavli Fellow (2009) NSF CAREER Award (2008) Roche First Prize, Switzerland (2002) First Innocentive Awardee (2001) Pfizer UK PhD Prize (2001) ORS Fellowship, University of Oxford (2000) Pathfinder Scholarship, University College London (1996) Advising and Grants: While specific students are not listed, Dr. Sintim has a well-established record of mentoring, recognized by awards such as the Allen Angerio Award. He has secured major funding through grants like the NSF CAREER Award and has advanced drug discovery projects to the level of co-founding KinaRx LLC, indicating strong translational grant and entrepreneurial success. His leadership as Associate Director of a major cancer research institute further underscores his role in guiding research teams and collaborative science. Labs and Teams: The Sintim Research Group at Notre Dame operates at the intersection of synthetic organic chemistry and biological signaling, with active projects in cancer, inflammation, and antibiotic discovery. The lab employs integrated computational and experimental workflows and collaborates widely, as seen in multi-institutional publications involving researchers in pharmacology, oncology, and immunology.

• Chemical Biology
• Medicinal Chemistry
• Biochemistry
• +13 more

Tyler Johnson, PhD, is an Associate Professor in the Department of Natural Sciences and Mathematics at Dominican University of California's School of Health and Natural Sciences. His expertise lies in Natural Products Chemistry , Bioorganic Chemistry , and Medicinal Chemistry , with a focus on biomedical applications. Johnson's research emphasizes discovering therapeutic lead compounds and molecular probes from marine and terrestrial natural products. His research team investigates chemotypes like mycothiazole , zampanolide , fijianolide , and latrunculin from Indo-Pacific marine sponges. These compounds exhibit potent cytotoxicity (IC50 1~5 nM) against cancer cell lines through mechanisms including microfilament disruption , mitochondrial complex I inhibition , and microtubule stabilization . Current work explores mycothiazole as a molecular probe for mitochondrial aging. Key publications span 2024-2002, covering topics from sponge-derived anticancer agents to inflammation modulation and environmental toxicology. Johnson's laboratory engages in large-scale natural product isolation, spectroscopic validation, and semi-synthetic medicinal chemistry to optimize therapeutic leads. His work integrates undergraduate and graduate students into interdisciplinary biomedical research.

• Natural Products Chemistry
• Bioorganic Chemistry
• Medicinal Chemistry
• +2 more

Professor Faye Rogers serves as Professor of Therapeutic Radiology at Yale University School of Medicine, holding multiple leadership positions including Associate Cancer Center Director for YCC Collaborative Excellence, Vice Chair for Collaborative Excellence in Therapeutic Radiology, Associate Director of the Yale MD-PhD Program, and Director of the Yale BioMed Amgen Scholars Program. Her work bridges radiation oncology, DNA repair mechanisms, and cancer therapeutics within Yale's comprehensive cancer research ecosystem. PhD from University of Maryland at Baltimore (1998) Postdoctoral Fellow at Yale School of Medicine Dr. Rogers' research focuses on the intersection of DNA repair mechanisms and cancer therapeutics, with particular expertise in triplex DNA structures, genomic instability, and targeted cancer therapies. Her work explores how DNA damage responses can be leveraged for therapeutic benefit, especially in breast neoplasms and other malignancies. Through her leadership in the DNA Damage and Genome Integrity program, she investigates novel approaches to disrupt cancer cell survival mechanisms while sparing healthy tissue. Her research has significant implications for radiation oncology, particularly in developing more precise and effective radiation-based treatments. Analysis of Dr. Rogers' publication record reveals a consistent trajectory in DNA repair mechanisms and cancer therapeutics, with increasing focus on translational applications. Her work demonstrates expertise in triplex DNA structures, RAD51 inhibition, and synthetic lethality approaches. Recent publications show a shift toward more clinically applicable research, particularly in targeting DNA repair pathways in specific cancer subtypes like IDH1-mutant cancers and PTEN-deficient glioblastomas. Her collaborative work with Peter Glazer and others demonstrates strong interdisciplinary connections between radiation oncology, molecular biology, and drug development. Leadership in Diversity, Equity & Inclusion Award (Yale School of Medicine, 2022) Translational Science Research Prize (Yale Cancer Center, 2022) Kingsley Fellowship in Medical Research Carl Storm Underrepresented Minority Fellowship NCI Research Supplement to Promote Diversity in Health-Related Research As Associate Director of the Yale MD-PhD Program and Director of the Yale BioMed Amgen Scholars Program, Dr. Rogers plays a pivotal role in mentoring the next generation of physician-scientists and supporting underrepresented minorities in biomedical research. Her leadership in collaborative excellence initiatives demonstrates commitment to fostering interdisciplinary research teams across Yale's scientific ecosystem. Through the YCC Collaborative Excellence program, she has secured significant funding for innovative cancer research that bridges basic science and clinical applications, particularly in the areas of DNA repair targeting and radiation oncology. Dr. Rogers leads research within Yale's Therapeutic Radiology department, with strong connections to the Radiobiology program and the Yale Cancer Center. Her work is integrated with the Program in Translational Biomedicine and the Yale Combined Program in the Biological and Biomedical Sciences. Through the BioMed Amgen Scholars Program, she provides critical research opportunities for undergraduate students, particularly those from underrepresented backgrounds, fostering talent in DNA repair research and cancer therapeutics.

• Apoptosis
• Biochemistry
• Breast Neoplasms
• +5 more

Eric W. Schmidt is a Distinguished Professor of Medicinal Chemistry at the University of Utah, with adjunct appointments in Biological Sciences and Chemistry. His research focuses on natural products chemistry, biosynthesis, synthetic biology, and pharmaceutical applications of marine animal microbiomes. University of California, San Diego (BS, PhD) Research areas include: Biosynthesis in animals and their microbiomes Synthetic biology approaches to chemical engineering Drug design from marine natural products Metagenomic analysis of symbiotic relationships Neuroactive compound discovery Antibiotic development against resistant pathogens His lab has pioneered methods for: Biosynthetic gene cluster identification Heterologous expression in E. coli Enzymatic modification of peptides Chemical analysis of marine invertebrates Recent publications highlight discoveries in: Marine animal chemical defense mechanisms Evolution of biosynthetic pathways Antibiotic resistance profiling Ionic channel-targeting compounds Peptide macrocyclization techniques Lipid-polyketide biosynthesis continuum Email: ews1@utah.edu Honors include: Distinguished Professor recognition

• Natural Products Chemistry
• Biosynthesis
• Synthetic Biology
• +5 more

Adam Caparco is the DiPietro Assistant Professor of Chemical Engineering at Northeastern University, with a 25% joint appointment in the Department of Chemistry and Chemical Biology. He leads the Caparco Research Group, focusing on agricultural and environmental biotechnology, enzyme immobilization, and protein assemblies. His work integrates plant virology, nanotechnology, and molecular engineering to address sustainability challenges in agriculture and environmental remediation. He is a member of the Institute for Plant-Human Interface and holds affiliations with Northeastern’s College of Engineering and School of Arts and Sciences. Education: B.S. in Chemical and Biomolecular Engineering from UCLA (2015), Ph.D. from Georgia Tech (2020) under Julie Champion and Andreas Bommarius, followed by a USDA NIFA Postdoctoral Fellowship at UC San Diego under Nicole Steinmetz. His research spans plant immunoengineering, biomanufacturing in plants, and protein-based nanomaterials for bioremediation. Research Interests Plant excretion pathways for pathogen defense and environmental remediation Design of immobilized enzymes for green chemical synthesis Plant virus nanoparticles for nucleic acid delivery and immunity modulation Multifunctional protein engineering for sustainable agriculture Recent articles highlight advancements in plant virus-based delivery systems, enzyme immobilization strategies, and nano-enabled precision agriculture. Awards include the USDA NIFA Postdoctoral Fellowship. Caparco advises graduate and undergraduate researchers, including Julia Hilgemberg Merlin (PhD ChE), Olha Bereziuk (PhD CCB), and Paul Carter (PhD ChE). He collaborates widely and seeks to expand interdisciplinary research in plant biotechnology. Labs/Teams: Caparco Research Group (EXP 420 lab, EXP 530B office) and the Institute for Plant-Human Interface.

• Agricultural Biotechnology
• Environmental Biotechnology
• Enzyme Immobilization
• +6 more